Skip to main content
Caplight Logo









Amathus Therapeutics

Amathus Therapeutics

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://amathustx.com

Last Round

Corporate Funding

Mar 17, 2021

Company Overview

Amathus Therapeutics is a biotechnology company that develops small-molecule therapeutics targeting organelle-specific chaperones for the treatment of neurodegenerative and renal diseases.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

small-molecule therapeuticsdrug discoverybiotechneurodegenerative diseasebiopharmamitochondrial dysfunctionrenal diseasechaperone modulatorsearly-stage biotechpreclinical researchtherapeutic pipelinedrug developmentpharma partnershipTRAP1 modulatorsdrug discovery platform

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Amathus Therapeutics Comparables

Compare Amathus Therapeutics with similar companies based on industry and business-model similarity.

Amathus Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Vincere Biosciences
89%
MitoRx Therapeutics
81%
Pretzel Therapeutics
80%

Amathus Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Corporate FundingMar 17, 2021

Amathus Therapeutics Investors

Notable investors and investment history

Amathus Therapeutics investors
InvestorRounds
Sanofi VenturesVC Round

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 17, 2021

    Merck & Co., Inc. led the corporate funding round.

Amathus Therapeutics Filings

Explore SEC and related filing metadata, where available.

Amathus Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Amathus Therapeutics's valuation, stock price, and market status.

Is Amathus Therapeutics a public or private company?

Amathus Therapeutics is a private company.

What is the current stock price of Amathus Therapeutics?

Amathus Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is Amathus Therapeutics worth (valuation)?

Valuation information for Amathus Therapeutics is not publicly available.

Can I buy Amathus Therapeutics stock?

Amathus Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Amathus Therapeutics's last funding round?

Amathus Therapeutics's most recent funding round was Corporate Funding on March 17, 2021.

Who are the main investors in Amathus Therapeutics?

Key investors in Amathus Therapeutics include Sanofi Ventures.

Will Amathus Therapeutics IPO soon?

No public IPO plans have been announced for Amathus Therapeutics.

How can I track Amathus Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Amathus Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range1
Year Founded2016
Last FundingMar 17, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?